Trump's push to speed up psychedelic research is sending shockwaves through mental health and markets

President Donald Trump has signed an executive order aimed at accelerating research and regulatory approval for psychedelic-assisted therapies, a move that's shaking up both the mental health landscape and the biotech market. The order directs federal agencies, including the FDA and NIH, to prioritize clinical trials and fast-track reviews for treatments using substances like psilocybin and MDMA, particularly for treatment-resistant depression, PTSD, and other severe mental health conditions.

One of the clearest early winners is Compass Pathways, a company developing psilocybin-based therapy for depression. Its U.S.-traded shares surged as much as 53% following the announcement, reflecting broader investor optimism about the sector. Other firms with psychedelic research pipelines also saw gains, signaling growing confidence that regulatory barriers may finally be easing after years of cautious oversight.

George Goldsmith, executive chairman of Compass Pathways, welcomed the move in a statement, saying the order recognizes the urgent need for innovation in mental health care. He emphasized that their work focuses on controlled, clinical settings-not recreational use-and that faster approvals could bring relief to millions who haven't responded to traditional antidepressants.

The executive action doesn't legalize psychedelics for general use. Instead, it pushes for expanded access through medical channels, encouraging the FDA to use existing fast-track and breakthrough therapy pathways. It also calls for increased funding for trials and coordination across health agencies to reduce bureaucratic delays that have slowed progress in the past.

Still, questions remain about who will ultimately benefit. While advocates see this as a long-overdue step forward, some warn that without cost controls and broad insurance coverage, these therapies could become available only to the wealthy. There are also concerns about ensuring patient safety and preventing misuse, even within clinical frameworks.

The order lands at a moment when public awareness of mental health is high, and dissatisfaction with current treatment options is growing. With suicide rates and depression diagnoses still elevated, especially among younger Americans, the pressure to explore new solutions has built steadily-across political lines.

Whether this executive push leads to widespread, accessible treatments or remains a narrow advance for a select few will depend on how agencies implement the directive, how insurers respond, and whether Congress follows up with sustained funding and policy support.